• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Donanemab in Early Alzheimer's Disease. Reply.

作者信息

Mintun Mark A, Wessels Alette M, Sims John R

机构信息

Eli Lilly, Indianapolis, IN

出版信息

N Engl J Med. 2021 Aug 12;385(7):667. doi: 10.1056/NEJMc2109455.

DOI:10.1056/NEJMc2109455
PMID:34379934
Abstract
摘要

相似文献

1
Donanemab in Early Alzheimer's Disease. Reply.多奈单抗用于早期阿尔茨海默病。回复。
N Engl J Med. 2021 Aug 12;385(7):667. doi: 10.1056/NEJMc2109455.
2
Donanemab in Early Alzheimer's Disease.多纳单抗用于早期阿尔茨海默病
N Engl J Med. 2021 Aug 12;385(7):666-667. doi: 10.1056/NEJMc2109455.
3
Donanemab leads to modest slowing of Alzheimer's progression, study finds.研究发现，多那奈单抗可使阿尔茨海默病的进展略有减缓。
BMJ. 2023 Jul 18;382:1659. doi: 10.1136/bmj.p1659.
4
Neurotoxic Soluble Amyloid Oligomers Drive Alzheimer's Pathogenesis and Represent a Clinically Validated Target for Slowing Disease Progression.神经毒性可溶性淀粉样寡聚体驱动阿尔茨海默病的发病机制，代表了一种经过临床验证的可减缓疾病进展的目标。
Int J Mol Sci. 2021 Jun 14;22(12):6355. doi: 10.3390/ijms22126355.
5
Prevalence and prognosis of Alzheimer's disease at the mild cognitive impairment stage.轻度认知障碍阶段阿尔茨海默病的患病率及预后
Brain. 2015 May;138(Pt 5):1327-38. doi: 10.1093/brain/awv029. Epub 2015 Feb 17.
6
[How to define Alzheimer's disease].[如何定义阿尔茨海默病]
Rev Prat. 2011 Sep;61(7):914-9, 921.
7
Presenilin 1 intronic polymorphism is not associated with Alzheimer type neuropathological changes or sporadic Alzheimer's disease.早老素1内含子多态性与阿尔茨海默病型神经病理改变或散发性阿尔茨海默病无关。
J Neurol Neurosurg Psychiatry. 1998 Apr;64(4):548-51. doi: 10.1136/jnnp.64.4.548.
8
Diffusion tensor imaging of white matter degeneration in early stage of Alzheimer's disease: a review.阿尔茨海默病早期白质退变的扩散张量成像：综述
Int J Neurosci. 2020 Mar;130(3):243-250. doi: 10.1080/00207454.2019.1667798. Epub 2019 Sep 24.
9
Lecanemab in Early Alzheimer's Disease. Reply.用于早期阿尔茨海默病的lecanemab。回复。
N Engl J Med. 2023 Apr 27;388(17):1631-1632. doi: 10.1056/NEJMc2301380.
10
Two-year follow-up of amyloid deposition in patients with Alzheimer's disease.阿尔茨海默病患者淀粉样蛋白沉积的两年随访
Brain. 2006 Nov;129(Pt 11):2856-66. doi: 10.1093/brain/awl178. Epub 2006 Jul 19.

引用本文的文献

1
Advances in JNK inhibitor development: therapeutic prospects in neurodegenerative diseases and fibrosis.JNK抑制剂开发的进展：在神经退行性疾病和纤维化中的治疗前景
Arch Pharm Res. 2025 Sep 8. doi: 10.1007/s12272-025-01566-w.
2
Repurposing Saroglitazar for neurodegenerative disorders: insight into molecular signalling pathways and neuroprotective modulations.将沙罗格列扎重新用于治疗神经退行性疾病：对分子信号通路和神经保护调节的深入了解。
Inflammopharmacology. 2025 Jun 23. doi: 10.1007/s10787-025-01805-y.
3
Driving research on successful aging and neuroprotection in Latin America: Insights from the inaugural symposium on brain resilience and healthy longevity.
推动拉丁美洲成功老龄化与神经保护研究：首届脑韧性与健康长寿研讨会的见解
Alzheimers Dement. 2025 Mar;21(3):e70037. doi: 10.1002/alz.70037.
4
Amyloid-Directed Antibodies: Past, Present, and Future.淀粉样蛋白导向抗体：过去、现在和未来。
J Alzheimers Dis. 2024;101(s1):S3-S22. doi: 10.3233/JAD-240189.
5
Alpha-lipoic acid alleviates cognitive deficits in transgenic APP23/PS45 mice through a mitophagy-mediated increase in ADAM10 α-secretase cleavage of APP.硫辛酸通过促进 ADAM10 α-分泌酶对 APP 的切割来减轻 APP23/PS45 转基因小鼠的认知缺陷。
Alzheimers Res Ther. 2024 Jul 19;16(1):160. doi: 10.1186/s13195-024-01527-3.
6
Discovery of Potential Drug Targeting Key Genes in Alzheimer's Disease: Insights from Transcriptome Analysis and Molecular Docking.阿尔茨海默病潜在药物靶点关键基因的发现：转录组分析和分子对接的启示。
J Mol Neurosci. 2024 May 27;74(2):56. doi: 10.1007/s12031-024-02208-4.
7
Proteomics revealed an association between ribosome-associated proteins and amyloid beta deposition in Alzheimer's disease.蛋白质组学揭示了核糖体相关蛋白与阿尔茨海默病中淀粉样β沉积之间的关联。
Metab Brain Dis. 2024 Feb;39(2):263-282. doi: 10.1007/s11011-023-01330-3. Epub 2023 Nov 29.
8
Comparison of relative change with effect size metrics in Alzheimer's disease clinical trials.阿尔茨海默病临床试验中相对变化与效应大小指标的比较。
J Neurol Neurosurg Psychiatry. 2023 Dec 14;95(1):2-7. doi: 10.1136/jnnp-2023-331941.
9
Precision Medicine Approach to Alzheimer's Disease: Rationale and Implications.精准医学方法治疗阿尔茨海默病：原理与意义。
J Alzheimers Dis. 2023;96(2):429-437. doi: 10.3233/JAD-230467.
10
Diagnostic accuracy of the plasma ALZpath pTau217 immunoassay to identify Alzheimer's disease pathology.血浆ALZpath pTau217免疫测定法用于识别阿尔茨海默病病理学的诊断准确性。
medRxiv. 2023 Jul 12:2023.07.11.23292493. doi: 10.1101/2023.07.11.23292493.